Featured

Phase II Clinical Trial NEO-201 in Combination with Pembrolizumab Detailed Study Information

Strattmont Group2021-10-28T11:57:03-04:00

The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...

Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at 6th Annual Neoantigen Based Therapies Summit, October 26-28th, Digital Event

Strattmont Group2021-10-28T15:47:15-04:00

Dr Massimo Fantini, Director of Research is Presenting the following Talk entitled : “Stability Tests...

Precision Biologics Commences Phase 2 Clinical Trial using NEO-201 and Pembrolizumab as a 2nd line Therapy in Patients with Solid Tumors

Strattmont Group2021-10-14T11:22:55-04:00

Precision Biologics announces that a Phase 2 Clinical Trial, combining NEO-201 with Pembrolizumab, is recruiting...

Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen Summit 20th-22nd April 2021

Strattmont Group2021-04-21T08:30:59-04:00

Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen summit, Clinical...

Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World Immunotherapy Congress, USA

Strattmont Group2021-03-26T10:04:55-04:00

Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World Immunotherapy Congress,...

Dr. Philip M. Arlen gives scientific presentation at World Vaccine & Immunotherapy Congress West Coast 2020, December 1 – 3, 2020

Strattmont Group2020-12-01T10:51:12-05:00

Dr. Philip M. Arlen gives scientific presentation at World Vaccine & Immunotherapy Congress West Coast...

Dr. Philip M. Arlen to give scientific presentation at two conferences

Strattmont Group2020-10-16T09:08:06-04:00

Dr. Philip M Arlen, MD, President and CEO is Presenting the Following Talk at the...

Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer

Strattmont Group2020-08-27T09:20:35-04:00

NIH Intramural Research Program (IRP) highlights Precision Biologics NEO-201 monoclonal antibody.

Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer

Strattmont Group2020-07-15T11:25:40-04:00

Precision Biologics in conjunction with our research collaborators at the National Cancer Institute (NCI) have...

Precision Biologics and the National Cancer Institute deliver 2 Poster Presentations at the AACR virtual meeting June 22-24th, 2020

Strattmont Group2020-06-25T17:47:53-04:00

Precision Biologics along with our collaborators at the National Cancer Institute present research data using...